← Back to headlines
Jefferies Reduces Upside for Arbutus Biopharma
Jefferies has lowered its upside potential assessment for Arbutus Biopharma Corporation, citing a higher probability of appeal.
17 Apr, 13:58 — 17 Apr, 13:58
Sources
Showing 1 of 1 sources
